SpyGlass Pharma Statistics
Total Valuation
SpyGlass Pharma has a market cap or net worth of $862.29 million. The enterprise value is $629.73 million.
| Market Cap | 862.29M |
| Enterprise Value | 629.73M |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SpyGlass Pharma has 33.45 million shares outstanding. The number of shares has increased by 708.11% in one year.
| Current Share Class | 33.45M |
| Shares Outstanding | 33.45M |
| Shares Change (YoY) | +708.11% |
| Shares Change (QoQ) | +67.80% |
| Owned by Insiders (%) | 4.28% |
| Owned by Institutions (%) | 18.25% |
| Float | 6.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.71 |
| P/TBV Ratio | 3.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.06, with a Debt / Equity ratio of 0.01.
| Current Ratio | 25.06 |
| Quick Ratio | 24.89 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -26.54% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$737,539 |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 21.04 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 67.92 |
| Average Volume (20 Days) | 79,797 |
Short Selling Information
The latest short interest is 1.14 million, so 3.41% of the outstanding shares have been sold short.
| Short Interest | 1.14M |
| Short Previous Month | 1.13M |
| Short % of Shares Out | 3.41% |
| Short % of Float | 17.56% |
| Short Ratio (days to cover) | 9.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -62.11M |
| Pretax Income | -56.05M |
| Net Income | -56.05M |
| EBITDA | -61.09M |
| EBIT | -62.11M |
| Earnings Per Share (EPS) | -$3.88 |
Balance Sheet
The company has $234.19 million in cash and $1.63 million in debt, with a net cash position of $232.55 million or $6.95 per share.
| Cash & Cash Equivalents | 234.19M |
| Total Debt | 1.63M |
| Net Cash | 232.55M |
| Net Cash Per Share | $6.95 |
| Equity (Book Value) | 232.36M |
| Book Value Per Share | 6.95 |
| Working Capital | 227.02M |
Cash Flow
In the last 12 months, operating cash flow was -$46.56 million and capital expenditures -$3.18 million, giving a free cash flow of -$49.74 million.
| Operating Cash Flow | -46.56M |
| Capital Expenditures | -3.18M |
| Depreciation & Amortization | 1.01M |
| Net Borrowing | n/a |
| Free Cash Flow | -49.74M |
| FCF Per Share | -$1.49 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SpyGlass Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -708.11% |
| Shareholder Yield | -708.11% |
| Earnings Yield | -6.50% |
| FCF Yield | -5.77% |
Analyst Forecast
The average price target for SpyGlass Pharma is $45.00, which is 74.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.00 |
| Price Target Difference | 74.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |